ArticleNPJ Parkinson's disease2025
Targeting the hypothalamic a11 nucleus to treat parkinsonian-like nociceptive impairments.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pain is a common non-motor symptom in Parkinson's disease (PD), yet treatment options remain limited due to incomplete understanding of underlying mechanisms. Using the 6-hydroxydopamine (6-OHDA) rat model, we combined pharmacological, behavioural, chemogenetic, electrophysiological, and immunohistochemical approaches to investigate dopaminergic modulation of nociception by the hypothalamic A11 projecting to the dorsal horn of the spinal cord (DHSC). We demonstrate that A11 dopaminergic neurons are the sole source of dopamine in the DHSC. Activation of both D1 and D2 receptors alleviated mechanical allodynia, while only D2 receptor stimulation improved thermal hyperalgesia and normalized wide dynamic range (WDR) neuron hyperexcitability. Selective chemogenetic activation of the A11-DHSC pathway reduced nociceptive hypersensitivity and improved WDR neuronal function in 6-OHDA rats. These findings establish a critical role of spinal dopaminergic signaling in PD-related pain and highlight the A11 region as a potential therapeutic target for pain management in PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.